ReviewJournal of medicinal chemistry2025
Pseudonatural Products for Chemical Biology and Drug Discovery.
Review in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A Topological and Spatial Analysis of FDA-Approved Drugs, Blood-Brain Barrier Permeants, Natural Products, and Metabolites.ChemMedChem · 2026Article
- Natural Products and Neuroregeneration: Rethinking Discovery Beyond Bioavailability Through Pseudo-Natural Product Design.Biomedicines · 2026Review
- Mapping Evolution of Molecules across Biochemistry with Assembly Theory.Journal of chemical information and modeling · 2026Article
- The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules.Journal of medicinal chemistry · 2026Article
- Merging photocatalysis with C-H insertions enabled switchable synthesis of indoles and indolines.Nature communications · 2026Article
- Design, Synthesis, and Biological Evaluation of Pseudo-Natural Products Inspired by Aryloctahydroindole Alkaloids.ChemMedChem · 2026Article
- Design, Synthesis, and Structural Evolution of Pseudo-Natural Product IDO1 Inhibitors and Degraders.Angewandte Chemie (International ed. in English) · 2026Article
- Recent Advances inMolecules (Basel, Switzerland) · 2025Review
- Update and ADMET Profile of the Latin American Natural Product Database: LANaPDB.Molecular informatics · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural product (NP) structures have provided invaluable inspiration for the discovery of bioactive compound discovery. In the pseudonatural product (PNP) concept unprecedented combinations of NP fragments combine the biological relevance of NPs with exploration of wider chemical space by fragment-based design. We describe the principles underlying the PNP design and discovery of selected PNPs with unexpected or novel bioactivity. Cheminformatic analyses of ChEMBL 32, the Enamine screening library, phase 1-3 clinical compounds, and approved drugs reveal that ca. 1/3 of historically developed biologically active compounds and of currently commercially available screening compounds are PNPs, and that PNPs are increasing over time. PNPs are 54% more likely to be found in clinical compounds versus nonclinical compounds, and 67% of recent clinical compounds are PNPs. 63% of the core scaffolds in recent clinical compounds are made up of just 176 NP fragments, which suggests that PNPs open up a multitude of unexploited opportunities for drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.